FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/07/2024
Back to search
Official data from USPTO
SOM BIOTECH
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
43
Latest update
12/07/2024
Trademark type
Combined
Nice classes
5, 42
Filing date
07/20/2022
Registration date
06/04/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/04/2024
Last transaction
06/04/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
85
Owner location
ES
Examiner
HARMON, RAYMOND
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the words "SOM BIOTECH" written in capital stylized letters. The word "SOM" is depicted in red, grey and black and it is represented in bigger letters than the word "BIOTECH", which is located under "SOM" and it is represented in grey in a smaller size.
Holders and representatives
Holders
SOM INNOVATION BIOTECH, S.A.
Representatives
Justin R. Young DTL Ltd.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the prevention of diseases of the nervous system; pharmaceutical preparations for treating metabolic disorders; chemical preparations for pharmaceutical purposes for the treatment of diseases of the nervous systemmetabolic disordersmalignant tumorsfor activating cellular functionfor cardiovascular and cerebrovascular diseasesfor the treatment of Parkinson's diseasefor the prevention of diseases of the respiratory systemfor gastro-intestinal disordersfor the treatment of infectious diseasesfor movement disordersfor oncologic diseasesfor immune system diseasesfor skeletal muscular diseasesfor hormone disordersfor skin diseasesfor ophthalmologic diseasefor gynecological diseasesfor hematological diseases and for pediatric diseases; pharmaceutical agents affecting metabolism; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for activating cellular function; medicines for the treatment of cardiovascular and cerebrovascular diseases; pharmaceutical preparations for the treatment of parkinson's disease; pharmaceutical preparations for the prevention of diseases of the respiratory system; pharmaceutical preparations for the treatment of rare diseases being hereditary movement disorders such as Huntington diseaseTourette diseasetardive dyskinesiahereditary muscular dystrophieshereditary metabolic disordershereditary neurological diseasesamyloidosisrare neurodegenerative diseasesmyotonic dystrophyspinal muscular atrophyidiopathic pulmonary fibrosismultiple sclerosisneurofibromatosisAcute Flaccid MyelitisDevic's syndromerare cancersneuropathic painELA and diabetes; pharmaceuticalsfor use in the field of treatment of hereditary diseases being Huntington's DiseasePhenylketonuriaTay SachsDuchenne Muscular DystrophyDystrophinopathiesGM2 gangliosidosesNiemann Pick Diseasehereditary amyloidosishereditary Parkinson's DiseaseadrenoleukodystrophyDravet syndromeBatten diseaseFragile X syndromeFriedrich AtaxiaLennox GastautGaucher diseasecystic fibrosisacute myeloid leukemiasickle cell disease; pharmaceutical preparations for the treatment of gastro-intestinal disorders; pharmaceutical products for the treatment of infectious diseases; pharmaceuticalsfor use in treatment of movement disorders; pharmaceutical preparations for use in oncology; pharmaceuticals for the treatment of immune system disease; pharmaceuticalsfor use in the treatment of skeletal muscular diseases; pharmaceuticalsfor use in the treatment of hormone disorders; pharmaceuticalsfor use in the treatment of skin diseases; pharmaceutical preparations for use in ophthalmology; pharmaceuticalsfor use in the treatment of gynaecological diseases; pharmaceuticalsfor use in the treatment of haematological diseases; pharmaceuticalsfor use in the treatment of paediatric diseases; reagents for use in medical genetic testing; clinical medical reagents; drug delivery agents consisting of compounds that modulate delivery of a wide range of pharmaceuticals; pharmaceutical preparationsdrug detoxifying agents; central nervous system stimulants; respiratory stimulants; cardiovascular drugs used in treating congestive heart failure (CHF); preparations for detecting genetic predispositions for medical purposes; cells for medical use; tumor suppressing agents; pharmaceutical preparations for treatment of tumorstumor antigens; biopharmaceuticals for the treatment of cancer
Class 42
Clinical research in the field of development of drugs discovered through artificial intelligence technology; biological research; chemical technological research in the field of development of drugs discovered through artificial intelligence technology; biomedical research services; research services in the fields of computation chemistry; medical and pharmacological research services in the field of drug discovery and development through artificial intelligence technology; research and development of vaccines and medicines; research and development in the field of microorganisms and cells; stem cell research services; research in the field of artificial intelligence technology; development of pharmaceutical preparations and medicines; implementation of preclinical trialsconducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of oncologyneurologymetabolic diseasesrespiratory diseasescardiovascular diseasesophthalmologic diseasesgastro-intestinal diseasesdermatological diseasesmusculoskeletal diseasesgynaecological diseasespaediatric diseasesinfectious diseasesmovement disordershormone disordersimmune system disordersneurodegenerative diseases; clinical trialsconducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of oncologyneurologymetabolic diseasesrespiratory diseasescardiovascular diseasesophthalmologic diseasesgastro-intestinal diseasesdermatological diseasesmusculoskeletal diseasesgynaecological diseasespaediatric diseasesinfectious diseasesmovement disordershormone disordersimmune system disordersneurodegenerative diseases; providing scientific information about the results of clinical trials for pharmaceutical products; consultancy pertaining to pharmacology; consultancy relating to research in the field of pharmacogenetics; consultancy relating to pharmaceutical research and development; chemistry consultation; providing information on the subject of scientific research in the field of biochemistry and biotechnology; laboratory analysis in the field of chemistry; design and development of medical technology; information technology (IT) consulting services for the pharmaceutical and healthcare industries; design and development of computer software for use with medical technology; design and development in relation to artificial intelligence technology; drug repositioning research; drug combination research
Publications
History of USPTO decisions and trademark events.
43 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/16/2024
FIMP
FINAL DISPOSITION PROCESSED
11/15/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/04/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/04/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
06/04/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
05/07/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/17/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
04/17/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/19/2024
PUBO
PUBLISHED FOR OPPOSITION
03/19/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/28/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/28/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/14/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/14/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/14/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/14/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
02/14/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/14/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
02/14/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/14/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/02/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/01/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/01/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/10/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
01/10/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/10/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/10/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/10/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/10/2024
RFNT
REFUSAL PROCESSED BY IB
08/28/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/05/2023
RFRR
REFUSAL PROCESSED BY MPU
08/05/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/30/2023
CNRT
NON-FINAL ACTION WRITTEN
06/29/2023
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
06/26/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/17/2023
CNRT
NON-FINAL ACTION WRITTEN
05/16/2023
DOCK
ASSIGNED TO EXAMINER
05/05/2023
MAFR
APPLICATION FILING RECEIPT MAILED
12/02/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/28/2022
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
11/25/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/17/2022
Continuous trademark protection
Get notified about every new filing that threatens SOM BIOTECH or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.